Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.0%

3 terminated/withdrawn out of 30 trials

Success Rate

86.4%

-0.1% vs industry average

Late-Stage Pipeline

23%

7 trials in Phase 3/4

Results Transparency

42%

8 of 19 completed trials have results

Key Signals

3 recruiting8 with results

Enrollment Performance

Analytics

Phase 1
8(40.0%)
Phase 3
6(30.0%)
Phase 2
4(20.0%)
N/A
1(5.0%)
Phase 4
1(5.0%)
20Total
Phase 1(8)
Phase 3(6)
Phase 2(4)
N/A(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials
NCT02808780Active Not Recruiting

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

Role: lead

NCT00606346Active Not Recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Role: lead

NCT04645355Phase 4Active Not Recruiting

Guselkumab Immunogenetics

Role: collaborator

NCT01314118Phase 2Completed

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Role: lead

NCT02315326Phase 1Completed

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Role: collaborator

NCT05300451Phase 2Enrolling By Invitation

Daratumumab in HLA Desensitization Prior to Transplantation

Role: collaborator

NCT01081730Completed

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

Role: lead

NCT01081717Completed

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

Role: lead

NCT05111210Recruiting

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis

Role: collaborator

NCT01833039Unknown

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Role: lead

NCT00658827Completed

Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis

Role: lead

NCT02103361Recruiting

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

Role: collaborator

NCT05290363Not ApplicableRecruiting

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

Role: collaborator

NCT01711814Phase 2Completed

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Role: collaborator

NCT02309580Phase 1Completed

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Role: collaborator

NCT03541174Phase 3Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

Role: collaborator

NCT03586570Phase 1Completed

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

Role: collaborator

NCT04162366Phase 3Withdrawn

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

Role: collaborator

NCT03098550Phase 1Completed

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Role: collaborator

NCT01637402Phase 2Completed

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Role: collaborator